reason report
instrument sale declin pharma china outlook depend
rest biz
bottom line remain outperform agil given lead
posit chem energi maintain well-diversifi
posit across healthcar growth market pharma lst dx
agil two key market instrument sale biopharma
rev china rev step consider
quarter driven chines gener drug polici chang continu
weak china food test rev overal weak demand
small molecul across eu life scienc appli market
group lsag rev instrument qtr
expect stay flat year combin factor
lead agil lower full-yr org revenue guid
given china drug procur rule like expand beyond
initi citi see agil outlook lever increasingli
chemic busi rev therapeut oligo
product nucleic acid solut divis nasd genom
busi rev lower estim pt
instrument sale declin key end-market china
gener food test small molecul pharma instrument
purchas small molecul pharma china gener food market
slow drive declin lsag rev vs
growth street estimate
clear explan slowdown small molecul world-wide
china weak larg gener food see continu
pressur mp agil report expect op
fare better given limit exposur gener drug
china growth like mute drug polici expand addit
provinc china agil revenue softer expect
come roughli flat versu usual hsd growth addit agil
continu wait pickup food analysi issu agil
face last quarter chines ministri consolid agenc
final food regul china food account
agil rev believ alreadi reach bottom like
recoveri ahead view believ china gener busi
rev like see weak countri
volume-bas purchas polici expand addit provinc
outlook lever rest busi includ
therapeut oligo product diagnost genom group
dgg number unexpect headwind near term
expect outlook lever busi rev
compani inform svb leerink llc research
revenu us million ep exclud item amort intang
price-to-earnings lt ep growth
life scienc tool diagnost
year price history/av daili volume mil
pleas refer page import disclosur price chart analyst certif
launch new ga chromatographi gc product
recal agil therapeut oligo busi also expect
start deliv frederick facil come line
start see benefit rais opportun
per agil larg part capac spoken still
nasd ramp remain conserv view potenti upsid
drug indic reach market believ dgg
rev also continu deliv genom volum rise
full-year organ growth revenue guid
respect reiter ep guid
guid step midpoint china
rest world china expect
busi vs prior guid appear realist view
given moder compar organ growth
abat china small molecul expect estim
revs/ep vs prior revs/ep
rate agil share outperform price target view agil
posit believ compani hold lead posit environment chemic
food test market around world maintain well-diversifi posit across
healthcar biopharma life scienc tool lst diagnost compani also repres
margin expans opportun medium long-term spin-off keysight
electron manag busi becom pure-play life scienc tool lst compani
agil continu deliv improv adjust oper margin despit growth initi
believ achiev exceed longer term leadership
ceo mcmullen agil compet aggress multipl market deliv solid growth
biopharma sale maintain either posit across
end-market includ food environment chemical/energi emerg market post
solid growth agil posit capit given sizabl exposur geographi
intuvo product cycl could repres opportun current under-
appreci agil repres compani develop core root industri
chemic electron market year transform life scienc tool
technolog leader diversifi access lead end-market
agil share current trade ev/ebitda under-valued compar
life scienc tool peer group averag
believ ev/ebitda valuat provid best measur agil valu
month price target expect agil trade line averag lst group
ev/ebitda multipl result appli ev/ebitda multipl
ebitda estim arriv pt
primari risk price target includ
biopharma declin pose greatest risk agil margin expans plan declin
biopharma fund could highli impact agil revenu given revenu lever
biopharma industri believ gener biopharma price risk mute given
elect outcom howev impact regulatori chang could see
biopharma compani becom cautiou spend could impact capit
equip purchas includ agil slowdown biopharma fund would
result downsid risk estim valuat biomolecul forecast ramp
drug market mid-teen believ prolifer drive
use agil mass spectromet character molecul pronounc
slowdown biopharma core growth requir margin expans would
slowdown global budget research could pose downsid risk forecast tighten
budget govern academ fund could result lower revenu rel
estim agil much academ government exposur
competitor nevertheless slowdown academ spend could
headwind plan margin expans assum expect core growth furthermor
restrict global budget could result shift focu strategi growth could
increas oper risk declin government spend could risk downsid
forecast growth nih spend flat low-single-digit
soft demand emerg market could derail growth forecast geopolit risk emerg
market could disrupt oper downsid risk valuat forecast geopolit
risk could also impact agil strategi creat higher barrier entri exist futur
market agil oper numer intern market includ china middl east
europ macroeconom impact chines market could lead declin compani
revenu regul chines polici could also caus restrict oper lead
lower activ china question remain china concern detail
headwind could emerg polici risk
continu volatil energi chemic sector could impact growth agil
consider exposur revenu chemic energi industri agil expect
recoveri next year continu volatil crude oil could result downsid risk
agil expect low-single-digit growth next year volatil oil price could impact
budget next year spend certain countri dictat commod price
would lead lower spend chemic energi
dollar million except per share data
good sold
sg sale
 sale
oper expens sale
compani report svb leerink estim
